Identification of a Late Stage of Small Noncycling pTα−  Pre-T Cells as Immediate Precursors of T Cell Receptor α/β+  Thymocytes by Trigueros, César et al.
 
1401
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/10/1401/12 $2.00
Volume 188, Number 8, October 19, 1998 1401–1412
http://www.jem.org
 
Identiﬁcation of a Late Stage of Small Noncycling
 
pT
 
a
 
2 
 
Pre-T Cells as Immediate Precursors of
 
T Cell Receptor 
 
a
 
/
 
b
 
1
 
 
 
Thymocytes
 
By César Trigueros,
 
*
 
 Almudena R. Ramiro,
 
* 
 
Yolanda R. Carrasco,
 
*
 
 
Virginia G. de Yebenes,
 
*
 
 Juan P. Albar,
 
‡
 
 and María L. Toribio
 
*
 
From the 
 
*
 
Centro de Biología Molecular “Severo Ochoa,” and the 
 
‡
 
Departamento de Inmunología y 
Oncología, Centro Nacional de Biotecnología, Universidad Autónoma de Madrid, Cantoblanco, 
28049 Madrid, Spain
 
Summary
 
During thymocyte development, progression from T cell receptor (TCR)
 
b
 
 to TCR
 
a
 
 rear-
rangement is mediated by a CD3-associated pre-TCR composed of the TCR
 
b
 
 chain paired
with pre-TCR
 
a
 
 (pT
 
a
 
). A major issue is how surface expression of the pre-TCR is regulated
during normal thymocyte development to control transition through this checkpoint. Here,
we show that developmental expression of pT
 
a
 
 is time- and stage-specific, and is confined in
vivo to a limited subset of large cycling human pre-T cells that coexpress low density CD3.
This restricted expression pattern allowed the identification of a novel subset of small CD3
 
2
 
thymocytes lacking surface pT
 
a
 
, but expressing cytoplasmic TCR
 
b
 
, that represent late non-
cycling pre-T cells in which recombination activating gene reexpression and downregulation
of T early 
 
a
 
 transcription are coincident events associated with cell cycle arrest, and immedi-
ately preceding TCR
 
a
 
 gene expression. Importantly, thymocytes at this late pre-T cell stage
are shown to be functional intermediates between large pT
 
a
 
1
 
 pre-T cells and TCR
 
a
 
/
 
b
 
1
 
 thy-
mocytes. The results support a developmental model in which pre-TCR–expressing pre-T
cells are brought into cycle, rapidly downregulate surface pre-TCR, and finally become small
resting pre-T cells, before the onset of TCR
 
a
 
 gene expression.
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a
 
E
 
arly in T cell development, thymocytes that have suc-
ceeded in productive V-D-J rearrangements at the
TCR
 
b
 
 locus are selected for cellular expansion and further
maturation before the TCR
 
a
 
 gene is expressed (1–3). This
process, termed “
 
b
 
-selection,” is regulated by the pre-
TCR, which comprises the CD3 complex in association
with the TCR
 
b
 
 chain and the invariant pre-TCR
 
a
 
 (pT
 
a
 
)
 
1
 
chain (4–6). A key question has been whether surface ex-
pression is essential for the pre-TCR complex to exert its
regulatory function. Recent studies support that this may
be the case, since pre-TCR–induced thymocyte matura-
tion involves both the extracellular constant region and the
transmembrane region of TCR
 
b
 
 (7), and requires exit of
the pre-TCR from the endoplasmic reticulum/
 
cis
 
-Golgi
compartment (8). The question remains as to whether pre-
TCR signaling is triggered by binding to an extracellular
ligand or, alternatively, as proposed recently (9), whether
pre-TCR complexes become constitutively active as soon as
they reach the plasma membrane, where signaling molecules
are available. In this latter situation, pre-TCR activity might
be regulated by control of membrane expression. However,
extremely low levels of the pre-TCR complex (
 
z
 
100-fold
lower than those of the TCR
 
a
 
/
 
b
 
 on mature T cells) appear
to reach the plasma membrane of immature thymocytes (10),
a fact that has hindered the development of monospecific
anti–pre-TCR reagents and, hence, the study of pre-TCR
expression patterns on normal thymocytes.
Current data support the notion that one of the first con-
sequences of pre-TCR expression is the induction of a cell
cycle progression that results in the greatest expansion in
cell numbers that occurs in the developing thymus (1, 11).
In mice, this process is associated with differentiation of
CD44
 
lo
 
CD25
 
1
 
 into CD44
 
lo
 
CD25
 
2
 
 double negative (DN)
 
1
 
Abbreviations used in this paper:
 
 DN, CD4
 
2
 
CD8
 
2
 
 double negative; DP,
CD4
 
1
 
CD8
 
1
 
 
 
double positive; GFP, green fluorescent protein; PI, propid-
ium iodide; pT
 
a
 
, pre-TCR
 
a
 
; RAG, recombination activating gene; RT,
reverse transcription; SP, single positive; TEA, T early 
 
a
 
; FSC, forward
side scatter; FTOC, fetal thymic organ culture.
 
C. Trigueros and A.R. Ramiro contributed equally to this work.
  
1402
 
Noncycling pT
 
a
 
2
 
 Late Pre-T Cells
 
thymocytes, suggesting that the pre-TCR is first expressed
on the cell surface at this developmental transition (11).
Accordingly, CD44
 
lo
 
CD25
 
2
 
 thymocytes from normal
mice are large-sized cells expressing trace but distinguish-
able levels of TCR
 
b
 
 and CD3 (12). Similarly, the fraction
of large thymocytes present in TCR
 
a
 
-deficient mice as
well as in TCR
 
b
 
 transgenic recombination activating gene
(RAG)-1
 
 
 
mutant mice expresses low but stoichiometric
levels of TCR
 
b
 
 and CD3 (13, 14). A highly analogous
checkpoint may occur in T cell development in humans
during the transition from CD4
 
1
 
CD8
 
2
 
 TCR
 
a
 
/
 
b
 
2
 
 precur-
sors to CD4
 
1
 
CD8
 
1
 
 TCR
 
a
 
/
 
b
 
2
 
 double positive (DP) thy-
mocytes, as the latter cells are mostly large cycling cells, in
which TCR
 
b
 
 is part of a complex that is distinct from the
mature TCR
 
a
 
/
 
b
 
, and could be the pre-TCR (15).
The pre-TCR–induced cell cycle transition is, in turn,
associated with the downregulation of RAG-1 and RAG-2
gene transcription (16) and RAG-2 protein expression
(11), which is likely to be an important component of the
process of allelic exclusion at the TCR
 
b
 
 locus (3, 11).
However, RAG genes have to be reexpressed at a later
stage to allow rearrangements at the TCR
 
a
 
 locus (16).
Likewise, TCR
 
a
 
 germline transcription and, hence, ex-
pression of sterile T early 
 
a
 
 (TEA) transcripts, is later in-
duced as an obligatory early event in the opening of the
TCR
 
a
 
 locus for subsequent VJ
 
a
 
 rearrangement (17). This
terminal program is rapidly triggered in mice during, or
immediately after, the transition from CD44
 
lo
 
CD25
 
2
 
 
 
cy-
cling thymocytes to CD4
 
1
 
CD8
 
1
 
 DP resting thymocytes
(16–18). Accordingly, surface expression of the mature
CD3–TCR
 
a
 
/
 
b
 
 complex is first detectable on small non-
proliferating DP thymocytes (19, 20). However, progress
towards a more precise definition of the stages involved in
the transition from TCR
 
b
 
 to TCR
 
a
 
 locus rearrangement
has been hampered thus far, both in mice and in humans,
because previous attempts to demonstrate surface expres-
sion of the pre-TCR complex throughout normal thy-
mocyte development have been unsuccessful.
In this study, analysis performed with a polyclonal rabbit
Ab that recognizes an exposed epitope of the native human
pT
 
a
 
 protein revealed a restricted pattern of surface pT
 
a
 
expression during normal human pre-T cell development.
On the basis of surface CD3/pT
 
a
 
 expression and cell size,
we have identified a novel subset of small pre-T cells which
lack surface CD3/pT
 
a
 
 expression and are mostly in a non-
cycling state. Transition to this developmental stage is
shown to be associated with the induction of specific de-
velopmental events that precede expression of the TCR
 
a
 
gene. Interestingly, such small pT
 
a
 
2
 
 noncycling pre-T
cells are shown to be functional intermediates between
large pT
 
a
 
-bearing pre-T cells and the first thymocytes ex-
pressing the mature 
 
a
 
/
 
b
 
 TCR.
 
Materials and Methods
 
Isolation of Thymocyte Subsets.
 
Postnatal thymocytes isolated
from thymus samples removed during corrective cardiac surgery
of patients aged 1 mo to 3 yr were fractionated by centrifugation
on stepwise Percoll density gradients (LKB, Uppsala, Sweden), as
described elsewhere (21). Thymocytes from the 1.068 and 1.08
density layers were designated as large and small thymocytes, re-
spectively. Large thymocytes were depleted (
 
.
 
99% purity) of
mature T cells (
 
a
 
/
 
b
 
 and g/d), B cells, NK cells, and myeloid cells
by two rounds of treatment with magnetic beads (Dynabeads;
Dynal A.S., Oslo, Norway) coupled to the following mAbs: anti-
TCRa/b (BMA031 [reference 22]; provided by Dr. R. Kurrle,
Behringwerke AG, Marburg, Germany); anti-TCRg/d (TCRd1
[reference 23]; provided by Dr. M. Brenner, Brigham and
Women’s Hospital, Boston, MA); anti-CD19 (Dynal A.S.), anti-
CD56 (Leu-19; Becton Dickinson, San Jose, CA), and anti-
CD14 (3C10, TIB 228; American Type Culture Collection,
Rockville, MD). CD41CD81 thymocytes were magnetically
sorted from the recovered pool with anti-CD8–coated beads
(Dynal A.S.), and CD41CD82CD32 thymocytes were then
sorted from the CD8-depleted pool with anti-CD4–coated beads
(Dynal A.S.), as described (15). Cells in the former subset (re-
ferred to as large TCRa/b2 DP thymocytes) were either CD32
or CD3low. Isolation of the CD32 cells (referred to as large CD32
DP thymocytes) was performed by depletion of CD3low cells with
anti-CD3–coated magnetic beads (Dynal A.S.). To avoid cell
death induced by treatment with anti-CD3, large CD3low DP
thymocytes were isolated from the 1.068 fraction recovered after
two rounds of fractionation on Percoll gradients, followed by de-
pletion of T, B, NK, and myeloid cells, and anti-CD8 sorting, as
described above. Such large TCRa/b2 DP thymocytes consisted
almost entirely (95–99%) of CD3low cells.
Small thymocytes recovered from the 1.08 density layer were
depleted of TCRa/b1 thymocytes (either CD3int or CD3bright)
by anti-TCRa/b magnetic bead depletion as described above
for large cells. CD32 cells (termed small CD32 DP thymocytes)
were then isolated from the recovered population (.99%
CD41CD81) by anti-CD3 bead depletion (Dynal A.S.). Mature
TCRa/b1 single positive (SP) thymocytes were isolated as de-
scribed previously (15).
Flow Cytometry Analysis. Directly labeled mAbs against CD3
(Leu4-PE) and CD8 (Leu2a-FITC) were obtained from Becton
Dickinson; anti-CD4 (CD4-PE-Cy5) mAbs were purchased
from Caltag Laboratories, Inc. (San Francisco, CA). A PE-labeled
mAb against the human TCR Vb1 family (24) was obtained from
Serotec Ltd. (Kidlington, Oxford, UK). Unlabeled mAbs against
monomorphic determinants of either TCRa/b (BMA031) or
TCRg/d (TCRd1), or against the human TCR Va12.1 (25; pro-
vided by Dr. M. Brenner), were used in combination with goat
anti–mouse FITC- or PE-coupled F(ab9)2 Ig (Caltag Laboratories,
Inc.). Isotype-matched irrelevant mAbs (Caltag Laboratories,
Inc.) were used as negative controls.
For detection of cytoplasmic TCRb, cells were stained with
the anti-TCRb chain mAb bF1 (26; provided by Dr. M. Bren-
ner), as described elsewhere (15). Surface expression of pTa chain
was determined by sequential staining with a rabbit polyclonal Ab
(ED-1) derived in this study (see below), plus FITC-conjugated
goat anti–rabbit F(ab9)2 Ig (Southern Biotechnology Associates,
Inc., Birmingham, AL). Preimmune rabbit serum was used as
negative control. For peptide competition, peptide (100 mg/ml)
was first incubated with the anti-pTa serum for 1 h at room tem-
perature. Stained cells were analyzed in a flow cytometer (EPICS
XL; Coulter Corp., Hialeah, FL) as described previously (15).
Cell cycle analyses were performed by flow cytometry using a
doublet discrimination function in cells treated with 0.05% digi-
tonin (Sigma Chemical Co., St. Louis, MO), washed, and stained1403 Trigueros et al.
with 50 mg/ml of propidium iodide (PI; Sigma Chemical Co.), as
described elsewhere (15).
Generation of Polyclonal Anti–human pTa Abs. A synthetic pep-
tide corresponding to the human pTa sequence 61–82 (15), with
an additional Cys in the COOH-terminal region, was coupled to
Maleimide-activated KLH following the manufacturer’s instruc-
tions (Pierce Chemical Co., Rockford, IL). Rabbits were immu-
nized with 1 mg of the peptide–KLH conjugate in CFA (Difco
Laboratories Inc., Detroit, MI) and boosted 30 and 50 d later
with 0.5 mg of immunogen in IFA (Difco Laboratories Inc.). The
animals were bled 10 d after the last booster injection, and the
sera were purified by affinity chromatography (Sulfolink Coupling
gel; Pierce Chemical Co.) and tested for antipeptide reactivity with
a horseradish peroxidase–labeled polyclonal goat anti–rabbit IgG
(Nycomed Amersham plc, Little Chalfont, Bucks, UK) plus o-phen-
ylenediamine dihydrochloride (OPD; Sigma Chemical Co.).
Cell Transfections and Immunofluorescence Assays. C-myc tagging
was performed by PCR amplification of a complete pTa cDNA
contained in the Bluescript-KS II plasmid (Stratagene Inc., La
Jolla, CA) with the sense 59-GGG CCC GGA TCC ATA TGG
CCG GTA CAT GGC TG-39 and antisense 59-GGG GGA
TCC TCA CAG GTC TTC CTC GGA GAT CAG CTT CTG
CTC TCC GCC GGC AGC TCC AGC CTG CAG-39 prim-
ers, which contained the sequence coding for the 9E10 mAb–
reacting c-myc peptide. The PCR product was subsequently
BamHI digested and ligated into the pSRa vector (pSR-pTamyc
[reference 27]; provided by Dr. B. Alarcón, Centro de Biología
Molecular “Severo Ochoa”). The pTa–green fluorescent protein
(GFP) fusion was carried out by PCR amplification of a complete
pTa cDNA with the sense 59-GGG CCC GGA TCC ATA
TGG CCG GTA CAT GGC TG-39 and antisense 59-GGG
GGA TCC CCG GCA GCT CCA GCC TGC AG-39 primers
followed by digestion and ligation into the BamHI site of the
pEGFP-N1 plasmid vector (Clontech, Palo Alto, CA). An
EcoRI-NotI restriction fragment from the pPTa-EGFP vector
was subsequently ligated into the pcDNA3 plasmid vector (Invit-
rogen Corp., Carlsbad, CA). The TCRa (Va12.1) full-length
cDNA (AV12S1) was the gift of Dr. J.A. López de Castro (Cen-
tro de Biología Molecular “Severo Ochoa”). AV12S1 cDNA (28)
was cloned into the BamHI site of the pcDNA3 plasmid vector.
COS cells were transfected by electroporation with 5 mg of pSR-
pTamyc plasmid plus 20 mg of carrier pUC-19 plasmid DNA
(Promega Corp., Madison, WI), at 250V, 960 mF in a Gene
Pulser (Bio-Rad Laboratories, Richmond, CA) as described else-
where (27). Electroporated cells were then plated on coverslips.
SUP-T1 cells were electroporated with 30 mg of the pTa-GFP
or AV12S1-containing vectors as described above, and 24–48 h
afterwards transfected cells were plated into 96-well round-bot-
tomed plates at 105 cells/ml, grown in the presence of 1 mg/ml
G418 for 2 wk, and analyzed by flow cytometry.
For immunofluorescence detection, 24–48 h after transfection,
COS cells were fixed with 2% paraformaldehyde, washed in PBS,
and permeabilized with 0.1% saponin in PBS containing 1% BSA
as blocking agent. The coverslips were then sequentially incubated
with the 9E10 anti–c-myc mAb (CRL 1729; American Type
Culture Collection), the ED-1 anti-pTa rabbit antiserum, FITC-
conjugated goat anti–rabbit Ig, and Texas red–conjugated goat
anti–mouse F(ab9)2 IgG (Southern Biotechnology Associates, Inc.).
The coverslips were visualized on a Zeiss Axioskop microscope.
Northern Blot Analysis. Preparations of total RNA (10 mg)
isolated as described previously (15) were run on 1% agarose/
formaldehyde gels, transferred to nylon membranes, and hybrid-
ized with 32P-labeled cDNA probes corresponding to the TCR
Ca (PY1.4 [29]) or Cb (Jurb2 [30]) regions (provided by Dr.
T.W. Mak, The Ontario Cancer Institute, Toronto, Ontario,
Canada). The RAG-1 and RAG-2 cDNA probes (31) were the
gift of Dr. L.A. Turka (The Howard Hughes Medical Institute,
Ann Arbor, MI), and the human pTa cDNA probe was derived
in our laboratory (15). The TEA probe was generated by PCR
amplification (sense primer 59-TGG ATG GAT AGA GAC
AAG TGC-39 and antisense primer 59- CCT GCC CTG GGG
AAT AAT AGG-39) of the K562 erythroleukemia genomic
DNA and cloning in a pMOS Blue-T vector (Nycomed Amer-
sham plc). The fragment obtained by HindIII-EcoRI restriction
was used for Northern blotting. The same blot was subsequently
stripped and hybridized with a b-actin probe (15).
Reverse Transcription PCR Analysis. Total RNA (1 mg) was
reverse-transcribed into cDNA according to the manufacturer’s
protocol (Boehringer Mannheim, Mannheim, Germany). Equiv-
alent amounts of cDNA among different samples was estimated
by reverse transcription (RT)-PCR carried out for 18, 21, and 25
cycles with b-actin primers as described previously (15). Titration
of cycle number allowed us to perform densitometric analyses
(Bio-imaging BAS 1500; Fujifilm, Kanagawa, Japan) under non-
saturating conditions. Va degenerate primers used in combina-
tion with Ca primers enabled the amplification of all known hu-
man Va segments, as described (32). Specific amplifications were
detected by Southern blotting with a Ca probe (29).
Hybrid Human/Mouse Fetal Thymic Organ Cultures. The in vitro
generation of mature TCRa/b1 human T cells was analyzed
using a modification of the previously described hybrid human/
mouse fetal thymic organ culture (hu/mo FTOC [33]). In brief,
thymi removed from 15-d-old embryos of Swiss mice were pre-
cultured for 5–6 d in the presence of 1.35 mM dGuo (Sigma
Chemical Co.). The thymic lobes were then washed and cocul-
tured in hanging drops in Terasaki plates (Nunc, Inc., Roskilde,
Denmark) with either large CD3low (105 cells/lobe) or small
CD32 (106 cells/lobe) human pre-T cells. After 2 d, lobes were
transferred to filters (Millipore Corp., Bedford, MA), which were
layered over gelfoam rafts and cultured in IMDM supplemented
with 2% human AB serum and 5% FCS (GIBCO BRL, Paisley,
UK). Surface staining of human cells was performed at the indi-
cated culture periods, and flow cytometric analyses were then
performed on electronically gated CD451 human cells.
Results
Surface CD3 Expression and Cell Size Define Distinct Sub-
sets of Human TCRa/b2 DP Thymocytes. We have previ-
ously identified a subset of large cycling CD41CD81 hu-
man thymocytes in which the TCRb chain is expressed as
part of a complex distinct from the mature a/b TCR,
likely the pre-TCR (15). According to their size, such
TCRa/b2 DP thymocytes could be selectively isolated
from the fraction of large cells recovered from Percoll den-
sity gradients (approximately one third of total unfraction-
ated thymocytes), whereas conventional TCRa/b1 DP
thymocytes were more common with the small-sized cell
fraction (around two thirds of total thymocytes [15]). Since
human thymocytes typically coexpress CD3 and the a/b
TCR in stoichiometric amounts, CD3 expression studies
similarly defined a differential distribution of cell subsets
among Percoll-fractionated thymocytes (Table 1). How-
ever, analysis of the correlated expression of CD3 versus1404 Noncycling pTa2 Late Pre-T Cells
TCRa/b revealed that, although most large TCRa/b2
thymocytes were CD32, a distinct proportion of them ex-
pressed low but detectable levels of CD3 (Fig. 1). These
large CD3low TCRa/b2 thymocytes did not represent g/d
T cells, as expression of the g/d TCR was exclusively de-
tected on large TCRa/b2 thymocytes with a CD3bright
phenotype (Fig. 1, and data not shown). Unexpectedly,
CD32 and CD3low cells were also recovered from the small
cell fraction (Fig. 1). Forward scatter (FSC) analyses ruled
out the possibility that such cells represented large-sized
contaminants (Table 1). Moreover, in contrast to large
CD3low thymocytes, essentially all CD3low small cells (15–
20% of total small thymocytes) coexpressed the a/b TCR.
However, small CD32 thymocytes were phenotypically
similar to CD32 large cells in that they expressed neither
the a/b nor the g/d TCR (Fig. 1, and data not shown). As
both large and small CD3low thymocytes displayed a homo-
geneous CD41CD81 DP phenotype (see below), they
were phenotypically indistinguishable except for the ex-
pression of a/b TCR on small DP thymocytes, but not on
large DP thymocytes.
Surface Expression of pTa Chain Can Be Detected with an
Anti-pTa Ab. The above results prompted us to investi-
gate whether large thymocytes with the CD3low TCRa/b2
phenotype do represent pre-T cells expressing the pre-
TCR. However, this issue was difficult to approach be-
cause no appropriate reagents such as anti-pTa Abs or Abs
able to recognize the human TCRb chain on the cell sur-
face were available. Consequently, Abs were raised in rab-
bits against a synthetic peptide contained in the extracellu-
lar Ig-like domain of the human pTa molecule (15). The
specificity of the affinity-purified antisera was then assayed
by immunofluorescence microscopy of COS cells trans-
fected with a pTa cDNA, tagged with a c-myc epitope
that is recognized by the specific 9E10 mAb. Results in Fig.
2 A show that one of these anti-pTa antisera (ED-1) was re-
active against all c-myc1 transfectants (top panels), and that
both anti–c-myc and anti-pTa reagents displayed an identi-
cal intracellular recognition pattern (bottom panels), thus con-
firming the anti-pTa specificity of the ED-1 antiserum.
To determine whether the anti-pTa antiserum was also
able to recognize the pTa chain when expressed on the
cell surface, we next derived pTa stable transfectants from
the human T cell line SUP-T1, which expresses TCRb
(Vb1.1) in the absence of a functional TCRa chain and,
hence, lacks surface TCRa/b heterodimers (34). As a
Table 1. FSC Analysis and Relative Cell Numbers of Human Thymocyte Subsets as Defined by Their CD3 Expression Levels
Thymocyte fraction
Subset Total thymocytes Large thymocytes Small thymocytes
relative no.
(%) 6 SD
mean
FSC 6 SD
relative no.
(%) 6 SD
mean
FSC 6 SD
relative no.
(%) 6 SD
mean
FSC 6 SD
CD32 22 6 4.8 357 6 12.1 28 6 4.9 358 6 12.0 19 6 2.2 333 6 17.2
CD3low 21 6 4.5 377 6 14.3 25 6 5.6 395 6 19.5 17 6 2.4 342 6 22.3
CD3int 31 6 3.4 335 6 22.3 13 6 2.7 346 6 20.0 45 6 4.6 313 6 14.3
CD3bright 24 6 4.6 340 6 11.6 29 6 5.1 330 6 12.2 17 6 6.1 329 6 11.1
Postnatal thymocytes were fractionated into large and small cells on Percoll density gradients. CD32, CD3low, CD3int, and CD3bright subsets from
each fraction were analyzed for cell size by flow cytometry (mean FSC 6 SD of 10 independent experiments). Unfractionated total thymocytes are
included for comparison.
Figure 1. Cell surface phenotype of total and Percoll-fractionated large
and small thymocytes. Successive thymocyte differentiation stages charac-
terized by their CD3 expression levels as negative (neg), low, intermediate
(int), and bright are differentially distributed within large- and small-sized
Percoll-separated thymocytes (shaded monoparametric histograms). Background
values were obtained with isotype-matched irrelevant mAbs (unshaded histo-
grams). Each thymocyte fraction was analyzed by two-color flow cytometry
for the expression of TCRa/b (BMA031) versus CD3. Background values
were determined with isotype-matched irrelevant mAbs.1405 Trigueros et al.
pTa-GFP chimeric protein was used in these studies, reac-
tivity of the anti-pTa antiserum could be analyzed by flow
cytometry on stable transfectants traced by their GFP ex-
pression. As shown in Fig. 2 B, such GFP1 transfectants ex-
pressed low but detectable levels of CD3, but were unreac-
tive with the BMA031 mAb which recognizes a common
epitope of the TCRa/b dimer (22). In contrast, both
TCRa/b and CD3 were detected on SUP-T1 clones sta-
bly transfected with a TCRa chain (Va12.1), whose expres-
sion could be followed with the anti-Va12.1 mAb 6D6 (25).
Interestingly, a reciprocal expression pattern was observed
when surface staining was performed with the anti-pTa Ab
plus anti-CD3. Thus, pTa (GFP1) transfectants, but not
TCRa (Va12.1
1) transfectants, were reactive with the anti-
pTa antiserum and coexpressed CD3 in stoichiometric
amounts (Fig. 2 B). It is worth noting that expression of the
endogenous TCRb could be specifically detected with an
anti-Vb1 mAb (24) on both cell types. Strikingly, levels of
TCRb expressed on pTa1 transfectants were consistently
lower than those on TCRa-expressing clones, although in
both cases, either pTa or TCRa was coexpressed with
TCRb in stoichiometric amounts (Fig. 2 B). As a whole,
these data suggest that the ED-1 antiserum was able to spe-
cifically detect pTa-containing surface complexes which
likely comprise CD3-associated TCRb-pTa heterodimers,
the hallmark of the pre-TCR complex.
Surface pTa Expression Is Restricted In Vivo to Large-sized
CD3low TCRa/b2 DP Thymocytes. Having established that
the anti-pTa antiserum recognized specifically pTa-contain-
ing surface complexes, we wished to examine whether
pTa was actually expressed on the surface of TCRa/b2
primary thymocytes. To this end, Percoll-fractionated large
and small DP thymocytes depleted of CD3int and CD3bright
cells (including both TCRa/b1 and TCRg/d1 cells) were
analyzed by flow cytometry for their reactivity with the
anti-pTa Ab. As expected, both isolated DP cell subsets
were exclusively composed of CD32 and CD3low cells (Fig.
3 A). CD3low thymocytes made up z50 and 30% of the
large- and small-sized DP thymocytes, respectively. Of
these, only small CD3low thymocytes coexpressed the a/b
TCR (see above), albeit at low levels, suggesting that they
were representative of the developmental onset of TCRa/b
expression. As shown in Fig. 3 A, such cells were unreac-
tive with the anti-pTa Ab. Expression of pTa was negative
as well on CD32 DP thymocytes, regardless of their cellular
size. In contrast, essentially all large CD3low cells displayed a
low but detectable reactivity with the anti-pTa Ab, thus
providing direct evidence that pTa-containing complexes
are expressed in vivo on the surface of normal pre-T cells.
That this low level staining is specific was demonstrated by
showing that it could be completely inhibited by the spe-
cific pTa peptide (Fig. 3 B). It is worth noting that pTa
and CD3 were coexpressed on large CD3low thymocytes in
a stoichiometric-like fashion similar to that observed on
SUP-T1 pTa transfectants (Fig. 2 B), suggesting that the
pTa-containing complex expressed on the former cells did
correspond to the CD3-associated pre-TCR.
Developmental Status of Subsets of TCRa/b2 DP Thy-
mocytes. The above results allowed a novel subdivision of
the TCRa/b2 DP compartment into three individual sub-
sets of thymocytes defined as large DP CD32, large DP
CD3low, and small DP CD32. Because pTa expression was
Figure 2. Specificity of anti-pTa ED-1 antiserum by immunofluores-
cence microscopy and flow cytometric analysis of pTa transfectants. (A)
COS cells were transfected with a human pTa cDNA tagged with a
c-myc epitope. After fixation and permeabilization, cells were sequen-
tially stained with the affinity-purified anti-pTa ED-1 rabbit antiserum
and the 9E10 anti–c-myc mAb. FITC-coupled goat anti–rabbit Ig and
Texas red–coupled goat anti–mouse IgG were used as second Abs, re-
spectively. Original magnification: 3400 (top panels) and 3630 (bottom
panels). (B) SUP-T1 human T-lineage cells were transfected either with a
productively rearranged human TCRa (Va12.1) cDNA or with a pTa-
GFP cDNA. Stable transfectants characterized, respectively, as Va12.11 or
GFP1 by flow cytometry (shaded monoparametric histograms) were assayed
for their reactivity with anti-TCRa/b and anti-CD3 mAbs (top biparamet-
ric histograms), or with ED-1 anti-pTa antiserum and anti-CD3 (middle
histograms). Coexpression of endogenous TCRb chain (Vb1) with either
pTa or TCRa (Va12.1) was assayed on pTa-GFP and TCRa transfec-
tants, respectively (bottom histograms). Background values were determined
with preimmune rabbit serum and isotype-matched irrelevant mAbs.1406 Noncycling pTa2 Late Pre-T Cells
restricted to large DP CD3low thymocytes, we wanted to
investigate further the developmental status of the distinct
pTa1 and pTa2 populations in order to improve definition
of their precursor–product relationships. To this end, the
three cell subsets were independently isolated and exam-
ined for their respective patterns of TCRb, TCRa, and
pTa gene expression. Northern blot analysis shown in Fig.
4 A revealed that both the 1.3-kb mature and the 1.0-kb
immature TCRb transcripts were expressed in the three
subsets of TCRa/b2 DP thymocytes, regardless of their
cellular size and CD3 phenotype. In contrast, TCRa tran-
scription was undetectable in all of them, but occurred at
high levels in mature SP thymocytes included as control.
As expected, CD41CD82CD32 cells, which represent up-
stream precursors of the TCRa/b2 DP thymocyte pool
as a whole (15), lacked both TCRb and TCRa mature
transcripts, but expressed 1.0-kb TCRb mRNA. There-
fore, we concluded that the three TCRa/b2 DP subsets
identified in this study include cells that have already com-
pleted TCRb, but not TCRa, gene rearrangement and
transcription, indicating that they represent discrete pre-T
cell stages along the pathway of T cell development. As ex-
pected of pre-T cells, all three cell types expressed pTa
mRNA, with higher levels in the large CD32 subset. Max-
imal pTa expression was found in the more immature
CD41CD82CD32 thymocytes (Fig. 4 A). A more sensi-
tive RT-PCR analysis of these very same populations con-
firmed the patterns of TCRb and pTa expression obtained
by Northern blotting (not shown). However, it revealed
that TCRa transcription had occurred, albeit at low levels,
in small CD32 thymocytes, whereas it was completely ab-
sent from both the CD32 and the CD3low subsets of large
pre-T cells (Fig. 4 B). Based on these results, we concluded
that small DP CD32 thymocytes represented the particular
stage at which TCRa gene rearrangement and transcrip-
tion are initiated during human T cell development; there-
fore, this subset was placed at the latest pre-T cell stage,
downstream of both subsets of large pre-T cells.
Additional support for the proposed model came from
studies aimed at investigating the TEA and RAG gene
transcription patterns displayed by the three pre-T cell sub-
sets. TEA is a TCRa germline transcript whose expression
seems to be an obligatory early event in the opening of the
TCRa locus for subsequent rearrangement (17). As Va to
Ja recombination necessarily involves deletion of the TEA
region (17), we reasoned that the onset of TCRa gene ex-
pression should necessarily be accompanied by a reciprocal
shutdown of TEA transcription. Northern blot analysis
performed with a specific TEA probe generated in this
study revealed that TEA transcription had not been in-
duced in early CD41CD82CD32 thymocytes, but oc-
curred at high levels in large CD32 DP thymocytes, and
was maximal in pTa1 pre-T cells (Fig. 4 A). However, it
was sharply downregulated in small CD32 thymocytes,
thus supporting the notion that the onset of TCRa gene
expression concurs with a decrease in TEA transcription,
these being coincident events in the transition from large to
small pre-T cells. A reciprocal pattern of RAG gene ex-
pression was observed at this developmental point after hy-
bridization with RAG-1– and RAG-2–specific probes
(Fig. 4 A). Thus, although RAG-1 and RAG-2 transcripts
were detected at similarly high levels in CD41CD82CD32
and large DP CD32 thymocytes, their expression was five-
to eightfold lower in pTa1 pre-T cells. Interestingly, max-
imal transcription levels of both genes corresponded to
small CD32 pre-T cells. These results suggest that RAG
gene expression is selectively turned down in pre-TCR–
expressing pre-T cells, and is later regained in small pre-T
cells, allowing rearrangements at the TCRa locus to occur.
TCRb Chain Expression and Cell Cycle Analysis of Subsets
of Pre-T Cells. Formation and expression of the pre-TCR
is claimed to immediately promote a cell cycle transition,
which results in expansion and selection (b-selection) of the
pool of pre-T cells deemed useful by virtue of successful
Figure 3. Analysis of surface
pTa chain expression on normal
human thymocytes. CD41CD81
DP cells were isolated from Per-
coll-separated large and small
thymocytes after depletion of
CD3int and CD3bright cells. (A)
Each cell subset was indepen-
dently analyzed by two-color
flow cytometry for CD4 versus
CD8 expression (top panels), and
for their reactivity with anti-
TCRa/b and anti-CD3 mAbs
(middle panels), or with anti-pTa
and anti-CD3 (bottom panels).
Background values were ob-
tained with preimmune rabbit
serum and isotype-matched irrel-
evant mAbs. (B) Peptide compe-
tition assay. Large DP TCR-
a/b2 thymocytes were stained
with ED-1 anti-pTa rabbit anti-
serum after PBS (left) or specific
pTa peptide (right) incubation
(shaded areas). Unshaded areas,
Background fluorescence.
Figure 4. Analysis of tran-
scriptional regulation of relevant
genes involved in pre-T cell de-
velopment. (A) Northern blots
of total RNA isolated from the
indicated populations were se-
quentially hybridized with the
cDNA probes indicated (left).
b-Actin mRNA expression served
as internal control. (B) RT-PCR
analysis of TCRa gene tran-
scription. cDNA samples were
amplified by using a pan-Va
primer in concert with a Ca-
specific primer. Equivalence of
cDNA among different samples
was assessed by RT-PCR using
b-actin primers under nonsat-
urating conditions. Sizes of the
bands are indicated at the right
(kb [A] or bp [B]).1407 Trigueros et al.
TCRb chain expression (1, 11). Therefore, the prediction
would be that all cells downstream of the pre-TCR–expres-
sing pre-T cell stage should show evidence of b-selection.
To address this issue, pre-T cell subsets were independently
analyzed by flow cytometry for their DNA content as well
as expression of cytoplasmic TCRb protein. Results shown
in Fig. 5 A revealed that essentially all (.90%) large pTa1
as well as small CD32 pre-T cells expressed cytoplasmic
TCRb; therefore, both cell subsets comprise b-selected
pre-T cells. Unexpectedly, however, only 50–80% of large
CD32 DP thymocytes (50% in this particular experiment)
expressed cytoplasmic TCRb, whereas the remaining 30–
50% were TCRb2. Such a differential expression of cyto-
plasmic TCRb defined two distinct cell subsets of large
CD32 pre-T cells which could thus be placed on either
side of the b-selection process.
Formal support for this notion came from additional
flow cytometric studies that addressed directly the cell cycle
status of either the TCRb1 or the TCRb2 subsets of large
CD32 pre-T cells. As shown in Fig. 5 B, double staining
with anti-TCRb and PI demonstrated that essentially all
(.90%) large CD32 pre-T cells lacking TCRb were ar-
rested in the G0/G1 phase of the cell cycle, whereas, as ex-
pected of b-selected thymocytes, TCRb1 CD32 pre-T
cells featured a high proportion (up to 55%) of cells in S/
G2/M. This is consistent with 30% of bulk CD32 pre-T
cells being in S/G2/M (Fig. 5 A). Therefore, TCRb2 large
pre-T cells are strong candidates for cells immediately be-
fore b-selection, and most likely immediately downstream
of the CD41CD82CD32 precursor stage, which was es-
sentially composed of TCRb2 thymocytes (.95%) dis-
playing only a background level (,10%) of cells in S/G2/M
(Fig. 5 A). As expected of b-selected thymocytes, large
pTa1 pre-T cells were highly enriched in cycling cells
(z55% in S/G2/M). However, TCRb expression could
not be associated with an active cycling state in small CD32
pre-T cells. Rather, these cells typically displayed only
background levels of cells in S/G2/M (,15%), with a sub-
stantial fraction of them (.50%) in the G2/M phase (Fig. 5
A). As an additional indicator of their resting state, small
CD32 pre-T cells were shown to display exclusively the
fast hypophosphorylated form of retinoblastoma (not
shown). We thus concluded that most, if not all, small
CD32 DP thymocytes are noncycling pre-T cells that have
already passed through b-selection. This, in turn, suggests
that b-selected large pre-T cells may normally lose surface
pre-TCR expression and return to slow cycle conditions
before the onset of TCRa gene expression. As a whole,
these data provide strong evidence that small resting pre-T
cells represent the latest pre-T cell stage in human thy-
mocyte development, immediately upstream of conven-
tional DP TCRa/b1 resting thymocytes.
Small CD32 Pre-T Cells Are Functional Intermediates be-
tween Large CD3low Pre-T Cells and TCRa/b1 DP Thy-
mocytes. To seek direct evidence that small CD32 DP
thymocytes represent the normal progeny of large pre-
TCR–expressing pre-T cells in the pathway of T cell dif-
ferentiation, highly purified large CD3low pre-T cells
(.98% pure) were analyzed for their developmental fate in
a hybrid hu/mo FTOC system. The pattern of differentia-
Figure 5. Intracytoplasmic TCRb chain expression and DNA content analysis of TCRa/b2 thymocyte subsets. (A) Flow cytometry analysis of CD3
surface expression (top panels) or intracytoplasmic (ic) TCRb ( b F1) expression (middle panels) of CD41CD82CD32, large DP CD32, large DP
CD3lowpTa1, and small DP CD32 thymocytes isolated as described in Materials and Methods (shaded histograms). Unshaded histograms, Background fluo-
rescence. Cells from each subset were analyzed for DNA content by flow cytometry after staining with PI. Doublet discrimination ensured that only sin-
gle cells were counted. Percentages of cells in G0/G1, S, and G2/M are indicated (bottom panels). (B) Two-color flow cytometry analysis of TCRb chain
expression versus DNA content of large DP CD32 thymocytes. Cells were electronically gated based on intracytoplasmic (ic) TCRb chain expression (I,
TCRb2; II, TCRb1) and reanalyzed for DNA content.1408 Noncycling pTa2 Late Pre-T Cells
tion from several experiments was identical (Fig. 6 A): the
rapid appearance of CD32 DP cells (up to 60% by day 5 in
this experiment) with minimal differentiation into TCRa/b1
cells (.5%), followed by the generation of a major pop-
ulation of conventional DP thymocytes that coexpressed
CD3 and the a/b TCR at low to intermediate levels (85%
by day 17), and the later appearance of small numbers of
mature SP thymocytes (not shown). FSC analysis of the cells
harvested on day 5 in the experiment shown in Fig. 6 A
revealed that, by this stage, the cells that remained CD3low
had kept their original size, whereas the CD32 cells gener-
ated in the lobes were significantly smaller (mean FSC: 450
vs. 410, respectively). However, by day 17, essentially all
large cells had reverted to small cells, and thus, all TCRa/b1
progeny generated by this time (85%) were similar in size to
the remaining (15%) CD32 DP cells (mean FSC: 330, 335,
and 329, for CD32, TCRa/blow, and TCRa/bint cells,
respectively). Interestingly, total yields of viable human cells
increased progressively during the initial phase of culture,
resulting in a 15–20-fold increase of absolute cell numbers
by days 5–7, but cellular recoveries then stabilized or in-
creased modestly (up to 2–3 times) through the next 10–12 d,
and declined steadily thereafter.
The above data indicate that cell division in thymus
lobes reconstituted with large CD3low pre-T cells is exten-
sive and skewed to the early stages of culture. Therefore,
the high yields of TCRa/b1 DP progeny in FTOC are
mostly a reflection of cellular expansion of blast precursors,
presumably before transition to small CD32 pre-T cells.
This in turn suggests that differentiation into TCRa/b1
DP cells can occur in the absence of cell division from
small noncycling CD32 pre-T cells. To provide direct evi-
dence of precursor activity, we tested the capacity of highly
purified (.98%) populations of small CD32 DP thy-
mocytes to produce TCRa/b1 progeny in the FTOC sys-
tem. As shown in Fig. 6 B, a high proportion of both
TCRa/blow (20%) and TCRa/bint (50%) progeny was al-
ready seen in the thymic lobes at day 1, the earliest sam-
pling time. However, the number of TCRa/b1 progeny
did not increase in absolute terms thereafter, an expected
finding considering that all cells recovered by day 1 were
small-sized cells (mean FSC: 300, 293, and 290, for CD32,
TCRa/blow, and TCRa/bint cells, respectively). Thus, al-
though kinetics of TCRa/b1 cell generation were more
pronounced with small CD32 than with large CD3low
pre-T cells, total cell yields were substantially lower with
the small CD32 pre-T cell fraction. Based on the above
results, we concluded that small CD32 DP thymocytes
represent functional intermediates between large pre-T
cells and TCRa/b1 DP thymocytes.
Discussion
Considerable progress has recently been made in defin-
ing the role that preantigen receptors, namely the pre-B
cell receptor and the pre-TCR, play in lymphocyte devel-
opment. It is now established that both receptors direct in
an analogous way the survival, expansion, and clonality of
pre-B and pre-T lymphocytes by triggering cell cycle acti-
vation and the simultaneous downregulation of RAG genes
(10, 11). However, less is known about the mechanisms
that control terminal differentiation of lymphocyte precur-
sors thus selected, especially in the T cell lineage. This can
be partly attributed in both mice and humans to the lack of
experimental data concerning regulation of pre-TCR ex-
pression on the surface of primary thymocytes, a fact that
Figure 6. Phenotypic analysis
of the cellular progeny generated
after differentiation of large
CD3low and small CD32 pre-T
cells in a hybrid hu/mo FTOC.
Large CD3low ( A ) and small
CD32 (B) DP thymocytes, iso-
lated as described in Materials
and Methods, were analyzed by
three-color flow cytometry after
the indicated days of culture.
Phenotypic analyses were per-
formed on electronically gated
human cells characterized as
CD451 (not shown). Back-
ground fluorescence was deter-
mined by staining with isotype-
matched irrelevant mAbs.1409 Trigueros et al.
has hampered the definition of the developmental stages in-
volved in the transition from TCRb to TCRa rearrange-
ment. In this study, analysis performed with a polyclonal
rabbit Ab that recognizes an exposed epitope of the native
human pTa protein has provided evidence for a restricted
pattern of surface pTa expression during normal T cell de-
velopment in humans. Surface pTa versus CD3 expression,
together with cell cycle analyses, enabled a novel subdivi-
sion of the whole compartment of TCRb-expressing pre-T
cells into three distinct subsets of increasing maturity, and
allowed the identification of a late stage of small noncycling
pre-T cells representing the immediate precursors of
TCRa/b-bearing thymocytes. The definition of the pre-
cursor–product relationships between such pre-T cell sub-
sets, together with the characterization of the stage-specific
events associated with the developmental onset of TCRa
gene expression, namely exit from cell cycle, reexpression
of RAG genes, and downregulation of TCRa germline
transcription, collectively support the developmental scheme
depicted in Fig. 7.
The distinct pre-T cell stages defined in our model are
all included within a subset of CD41CD81 DP thymocytes
that lack the mature a/b TCR and represent, as a whole,
the downstream progeny of CD41CD82CD32 thymocyte
precursors (15). About one third of such DP TCRa/b2
thymocytes are larger in size than the remaining two thirds
and, thus, the two cell types have been defined, respec-
tively, as large and small pre-T cells. Although pTa tran-
scription is common to all pre-T cell stages, surface expres-
sion of the pTa protein is shown to be restricted to a
limited fraction (50%) of large-sized pre-T cells that coex-
press small but stoichiometric amounts of CD3. As neither
pTa nor CD3 is detectable on the rest of the large and
small pre-T cells, the coexpression of both molecules seems
to define the particular subset of primary pre-T cells in
which the pTa chain is paired with TCRb and associates
with CD3 to form the pre-TCR. However, attempts to
demonstrate coexpression of surface TCRb in vivo were
unsuccessful, essentially because neither anti-TCRb mAbs
useful for flow cytometry nor anti-pTa reagents suitable
for biochemical studies are yet available. Despite this, the
possibility that TCRb-pTa heterodimers associated with
CD3 are indeed expressed on pTa1 pre-T cells is strongly
supported by several independent findings: (a) low but stoi-
chiometric amounts of pTa and CD3 were specifically co-
expressed with endogenous TCRb on pTa transfectants
derived from a TCRa-deficient cell line; (b) we have pre-
viously shown that heterodimeric complexes containing
TCRb without TCRa could be immunoprecipitated from
unfractionated large DP TCRa/b2 thymocytes (15); (c)
others have noticed that large thymocytes from TCRa-
deficient and TCRb transgenic RAG-1 mutant mice ex-
press low but stoichiometric amounts of surface TCRb and
CD3 (13), similar to what has been reported for mouse
thymocytes from which a CD3-associated pTa-TCRb
heterodimeric complex has recently been characterized
(14); and (d) to date, no surface pTa expression has been
described without association with TCRb and CD3.
Figure 7. Proposed model of pre-T cell development in the human thymus. ic, Intracytoplasmic.1410 Noncycling pTa2 Late Pre-T Cells
Therefore, expression of surface pre-TCR complexes is
proposed in our model to be confined to the minor subset
of large pTa1 CD3low pre-T cells, whereas large pre-T
cells lacking detectable amounts of surface pTa and CD3
(z50% of all large DP TCRa/b2 thymocytes) are pro-
posed to be homogeneously negative for pre-TCR expres-
sion (Fig. 7). However, the latter cells represent a hetero-
geneous population in which a major fraction (50–80%)
have already passed b-selection, as indicated by their high
expression levels of intracellular TCRb (11), whereas the
remaining cells (20–50%) still lack cytoplasmic TCRb and
may thus represent intermediates between CD41CD82CD32
thymocytes and the first b-selected pre-T cells. It is highly
likely that such intermediates include the pool of precursor
thymocytes undergoing rearrangements at the TCRb lo-
cus, although they may also include cells carrying nonpro-
ductive Vb-Db-Jb joints on both TCRb loci, which may
thus be destined to die. Both possibilities, illustrated in Fig.
7, are compatible with the hypothesis that the human pre-
TCR does not participate, as does its murine counterpart,
in the transition to the DP stage (2, 3, 18). Rather, expres-
sion of CD8 appears to precede pre-TCR expression dur-
ing human T cell development.
An important aspect of our study was the observation
that virtually all large pre-T cells with cytoplasmic TCRb,
whether or not they display surface pTa chain expression,
were actively engaged in cell cycle, a characteristic previ-
ously associated with the process of b-selection (11). Con-
versely, DP thymocytes lacking TCRb protein were non-
dividing cells arrested at G0/G1. The finding that up to 40%
of cycling, b-selected pre-T cells did not express the puta-
tive pre-TCR is apparently difficult to reconcile with the
current idea that cell cycle activation involves signaling me-
diated through the pre-TCR (2, 3, 11). However, the pos-
sibility that undetectable, but functional, amounts of the
pre-TCR are expressed on the surface of such cycling
pTa2 pre-T cells cannot be formally excluded. Alterna-
tively, it is likely that, as proposed for pre-B cells at the
equivalent developmental point (35), b-selected pre-T cells
rapidly downregulate expression of the pre-TCR from the
cell surface while they are still in cycle. In this latter situa-
tion, it could be expected that the maintained expression of
surface pre-TCR in a short developmental window is both
necessary and sufficient to provide a sustained proliferation
signal that would allow pre-T cells to undergo a great cel-
lular expansion before turning back to slow cycle condi-
tions. Supporting this hypothesis, results from a recent
study have provided evidence that such a proliferation
phase corresponds in mice to nine rapid cell divisions that
last for z4 d and end at the small resting DP thymocyte
stage (36). This concurs with our finding that a major frac-
tion (about two thirds) of b-selected pre-TCR2 pre-T
cells in humans are small-sized, nondividing cells. Interest-
ingly, although such small pre-T cells do not yet express
the mature a/b TCR, they already transcribe low levels of
the TCRa gene. Thus, they are proposed to define the de-
velopmental point at which onset of TCRa gene rear-
rangement and transcription occurs, and are placed in our
model at the latest pre-T cell stage, immediately upstream
of the first TCRa/b-expressing DP thymocytes (Fig. 7).
Consistent with the above proposal, we found that indi-
cators of Va-Ja recombinase activity, such as RAG gene
reexpression and downregulation of TEA transcription, are
coincident and stage-specific events induced after entry of
late pre-T cells into the pool of small, resting cells. Thus, it
was observed that expression of RAG genes, which is
turned down after pre-TCR signaling (11, 18), is regained
in small pre-T cells, allowing rearrangements at the TCRa
locus to be initiated at this stage. Further, the demonstra-
tion that germline transcription of TCRa spans all cycling
pre-T cell stages but drops significantly in resting pre-T
cells also supports the concept that these cells are actively
rearranging their Va genes. Similarly, Ig L chain gene rear-
rangement is restricted to small, resting pre-B cells that rep-
resent the equivalent precursor stage along the B cell path-
way (35). In contrast to the proposal that small resting
TCR2 DP thymocytes are functional intermediates in the
T cell differentiation pathway, it is currently assumed that
these cells represent the large pool of end-stage products of
failed rearrangement attempts. However, recently pub-
lished data have shown that small noncycling TCR2 DP
thymocytes in the mouse are actually the physiological tar-
gets of the multiple rearrangements that occur at the
TCRa locus (20), and are subject to positive selection (21,
37). Direct evidence of the physiological relevance of small
resting CD32 pre-T cells in humans was further provided
by the demonstration that these cells are functional inter-
mediates between large pTa1 pre-T cells and TCRa/b1
DP thymocytes. Accordingly, as shown previously in mice
(19, 20), surface expression of the mature CD3–TCRa/b
complex can be first detectable on small nonproliferating
DP thymocytes.
As a whole, our results suggest that, after pre-TCR–medi-
ated cellular expansion, b-selected large pre-T cells may
normally downregulate surface pre-TCR expression and
return to slow cycle conditions before the onset of TCRa
gene expression. The proposed pattern of pre-TCR ex-
pression differs from previous hypothetical models in mice
postulating that mature TCRa/b and pre-TCR complexes
are coexpressed on the cell surface of late pre-T cells (10).
However, it is still possible that some of these cells are
cotranscribing pTa and TCRa genes. It is tempting to
speculate that, in that situation, both molecules compete
with each other for dimerization with TCRb, the affinity
of TCRa being higher than that of pTa. Alternatively, as
proposed in mice, another still unknown component of the
pre-TCR (i.e., the hypothetical VpreT) might be already
shut off at the earliest TCRa1 stages, hence preventing
surface expression of the whole pre-TCR complex (3). Fi-
nally, it must be stressed that the restricted pattern of sur-
face pTa expression shown in this study closely resembles
that of the surrogate light chain of the pre-B cell receptor
(35, 38). This emphasizes the similarities of early develop-
mental events associated with the transient expression of
both preantigen receptors during T and B cell develop-
ment.1411 Trigueros et al.
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